Binah Capital Group, Inc.BCGNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Latest News

defenseworld.net

Binah Capital Group (NASDAQ:BCG) versus Barings Participation Investors (NYSE:MPV) Financial Comparison

Barings Participation Investors (NYSE: MPV - Get Free Report) and Binah Capital Group (NASDAQ: BCG - Get Free Report) are both small-cap finance companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk and valuation. Analyst Ratings This is a

defenseworld.net

Federated Hermes (NYSE:FHI) vs. Binah Capital Group (NASDAQ:BCG) Head to Head Review

Binah Capital Group (NASDAQ: BCG - Get Free Report) and Federated Hermes (NYSE: FHI - Get Free Report) are both finance companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings and dividends. Profitability This table compares Binah Capital Group

defenseworld.net

Contrasting Silvercrest Asset Management Group (NASDAQ:SAMG) & Binah Capital Group (NASDAQ:BCG)

Binah Capital Group (NASDAQ: BCG - Get Free Report) and Silvercrest Asset Management Group (NASDAQ: SAMG - Get Free Report) are both small-cap finance companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, analyst recommendations and risk. Risk and Volatility Binah

defenseworld.net

Artisan Partners Asset Management (NYSE:APAM) vs. Binah Capital Group (NASDAQ:BCG) Head to Head Survey

Artisan Partners Asset Management (NYSE: APAM - Get Free Report) and Binah Capital Group (NASDAQ: BCG - Get Free Report) are both finance companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk. Earnings and Valuation This table

defenseworld.net

Binah Capital Group (NASDAQ:BCG) vs. KKR & Co. Inc. (NYSE:KKR) Critical Comparison

KKR and Co. Inc. (NYSE: KKR - Get Free Report) and Binah Capital Group (NASDAQ: BCG - Get Free Report) are both finance companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations. Risk and Volatility KKR and

seekingalpha.com

CG Oncology Undervalued Going Into A Busy 2026

CG Oncology is positioned as a leading contender in high-risk BCG-unresponsive NMIBC, with its oncolytic adenovirus, cretostimogene grenadenorepvec (creto). Creto's efficacy and safety data rival JNJ's Inlexo, with a 75.5% any-time CR rate, similar 12mo/24mo CR rates, a longer response duration, and notably fewer Grade 3+ adverse events. CGON targets $2B peak revenue in its primary indication, with meaningful upside from intermediate-risk, BCG-naïve, and muscle-invasive bladder cancer opportunities.

prnewswire.com

Johnson & Johnson's INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC

New data from Cohort 4 of the SunRISe-1 study show more than 95 percent of patients remained progression free at one year, with more than 92 percent not undergoing bladder removal Patients with this type of bladder cancer have limited choices beyond radical cystectomy, highlighting the need for newer therapies for bladder preservation RARITAN, N.J. , Dec. 5, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today that new data from the investigational Cohort 4 of the Phase 2b SunRISe-1 study show treatment with gemcitabine intravesical system resulted in high one-year disease-free survival (DFS), progression-free survival (PFS), and overall survival (OS) rates in patients with Bacillus Calmette-Guérin (BCG)-unresponsive, high-risk, papillary-only non-muscle invasive bladder cancer (NMIBC).1 These data were featured as a late-breaking oral presentation at the Society of Urologic Oncology (SUO) 2025 Annual Meeting and build upon data presented at the 2025 American Urological Association (AUA) Annual Meeting.

globenewswire.com

BINAH Capital Group Welcomes Recently Acquired Commonwealth Team to its Broker-Dealer Platform Through its Long-Standing Strategic Relationship with Merit Financial Advisors

Chicago-Based, $1.2 Billion Team Will Use PKS Investments as its Friendly Broker-Dealer Chicago-Based, $1.2 Billion Team Will Use PKS Investments as its Friendly Broker-Dealer

defenseworld.net

Critical Contrast: Binah Capital Group (NASDAQ:BCG) & Fairfax India (OTCMKTS:FFXDF)

Fairfax India (OTCMKTS:FFXDF - Get Free Report) and Binah Capital Group (NASDAQ: BCG - Get Free Report) are both finance companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, dividends, earnings, valuation, profitability, risk and institutional ownership. Profitability This table compares Fairfax India and

globenewswire.com

Binah Capital Group to Participate in NobleCon21 Conference in December

NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Binah Capital Group, Inc. (“Binah”, “Binah Capital” or the “Company”) (NASDAQ: BCG; BCGWW), a leading financial services enterprise that owns and operates a network of industry-leading firms empowering independent financial advisors, today announced that it will participate in the NobleCon21 conference, Noble Capital Markets' 21st Annual Emerging Growth Equity Conference, in Boca Raton, FL on December 4, 2025. Presenting for the company at 9:30 AM ET in Presentation Room 5 will be Craig Gould, Chief Executive Officer, and David Shane, Chief Financial Officer.

globenewswire.com

Binah Capital Group Reports Results for Third Quarter and First Nine Months of 2025

- Grew Total Revenue 10% Year-over-Year to $137.0 Million - - Assets Under Management (“AuM”) Increased 11% Year-over-Year to $30.0 Billion - - Net Income of $2.1 Million - - Increased EBITDA [*] to $5.8 Million from $1.0 Million in the Prior Year - NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Binah Capital Group, Inc. (“Binah”, “Binah Capital” or the “Company”) (NASDAQ: BCG; BCGWW), a leading financial services enterprise that owns and operates a network of industry-leading firms empowering independent financial advisors, today announced results for the quarter ended September 30, 2025. "In the third quarter this year, we again generated strong results, which reflects the appeal and performance of our differentiated RIA platform,” stated Craig Gould, Chief Executive Officer of Binah Capital Group.

globenewswire.com

Binah Capital Group Subsidiary, PKS Investments, Recognized as One of Albany's Best Places to Work Second Year in a Row

NEW YORK, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Binah Capital Group (NASDAQ: BCG) (“Binah” or the “Company”) is proud to announce that its subsidiary, PKS Investments (“PKS”), has once again been recognized as one of Albany's Best Places to Work by the Albany Business Review. This honor places PKS among the top large companies (100+ employees) in the Capital Region for employee satisfaction, engagement, and workplace culture.

globenewswire.com

Binah Capital Group Reports Second Quarter 2025 Results

- Grew Total Revenue 2% Year-over-Year to $42 Million - - Assets Under Management (“AuM”) Increased 11% Year-over-Year to $28 Billion - - Net Loss of $0.7 Million, Comparable to the Prior Year - - Increased EBITDA* to $1.0 Million from $0.6 Million in the Prior Year - NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Binah Capital Group, Inc. (“Binah”, “Binah Capital” or the “Company”) (NASDAQ: BCG; BCGWW), a diversified financial services enterprise that owns and operates a network of industry-leading firms empowering independent financial advisors, across brokerage, advisory, and insurance solutions, today announced results for the quarter ended June 30, 2025. "We are pleased to report another strong performance this quarter, further demonstrating our advisor-centric platform built to power growth,” stated Craig Gould, Chief Executive Officer of Binah Capital Group.

globenewswire.com

CORRECTION - Binah Capital Group Announces PKS Investments as Finalist in Two Categories for the 2025 Wealth Management Industry Awards

- Dual Recognition Underscores Binah's Unmatched Commitment to Leadership and Operational Excellence - - Dual Recognition Underscores Binah's Unmatched Commitment to Leadership and Operational Excellence -

globenewswire.com

Binah Capital Group Announces PKS Investments as Finalist in Two Categories for the 2025 Wealth Management Industry Awards

globenewswire.com

Binah Capital Group Reports First Quarter 2025 Results

- Grew Total Revenue 18% Year-over-Year to $49 Million - - Assets Under Management (“AuM”) Increased 3% Year-over-Year to $26 Billion - - Net Income of $1 Million - - Increased EBITDA 1 to $2.2 Million from $(0.0) Million in the Prior Year - NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Binah Capital Group, Inc. (“Binah”, “Binah Capital” or the “Company”) (NASDAQ: BCG; BCGWW), a leading financial services enterprise that owns and operates a network of industry-leading firms empowering independent financial advisors, today announced results for the quarter ended March 31, 2025. "We once again delivered strong results, which is a continued testament to our differentiated RIA platform,” stated Craig Gould, Chief Executive Officer of Binah Capital Group.

businesswire.com

IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the POTOMAC Phase III trial showed one year of treatment with AstraZeneca's IMFINZI® (durvalumab) plus standard-of-care BCG induction and maintenance therapy demonstrated a statistically significant and clinically meaningful improvement in disease-free survival (DFS) for patients with high-risk non-muscle-invasive bladder cancer (NMIBC) compared to BCG induction and maintenance therapy alone. The trial was not statistically pow.

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance